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Abstract  
Multiple lines of evidence show that soluble oligomer forms of amyloid β protein (Aβ42) are the most neuro-
toxic species in the brain and correlates with the degree of neuronal loss and cognitive deficit in Alzheimer’s 
disease. Although many studies have used mammalian cells to investigate oligomer Aβ42 toxicity, the use of 
more simple eukaryotic cellular systems offers advantages for large-scale screening studies. We have previ-
ously established and validated budding yeast, Saccharomyces cerevisiae to be a simple and a robust model 
to study the toxicity of Aβ. Using colony counting based methods, oligomeric Aβ42 was shown to induce 
dose-dependent cell death in yeast. We have adapted this method for high throughput screening by devel-
oping an absorbance-based growth assay. We further validated the assay with treatments previously shown 
to protect oligomer Aβ42 induced cell death in mammalian and yeast cells. This assay offers a platform for 
studying underlying mechanisms of oligomer Aβ42 induced cell death using gene deletion/overexpression 
libraries and developing novel agents that alleviate Aβ42 induced cell death.
Key Words: Alzheimer’s disease; amyloid toxicity; autophagy; Aβ42 oligomer; high-throughput screening; 
latrepirdine; neuroprotection; yeast model
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Introduction 
Alzheimer’s disease is an incurable neurodegenerative dis-
order featuring progressive loss of memory and ability to 
perform daily tasks ultimately leading to death. The disease 
is characterized by deposition of intracellular neurofibrillary 
tangles and extracellular amyloid plaques within the brain. 
The cerebral amyloid plaques are insoluble protein deposits 
associated with dystrophic neurites, inflammatory processes 
and a dense core comprising primarily of aggregated fibrillar 
forms of Aβ protein (Fraser et al., 1993). The amyloid β pro-
tein (Aβ) is a 40/42-amino acid product of amyloid precur-
sor protein and is found in the brains and cerebrospinal fluid 
of both healthy individuals and people with AD (reviewed in 
(Selkoe and Hardy, 2016)). Numerous isoforms of Aβ have 
been detected in the brain, however the AD brain exhibits 
markedly increased levels of the longer aggregate-prone 
isoform, Aβ42 [reviewed in Bharadwaj et al. (2009)]. Soluble 
oligomeric form of Aβ42 correlates with cognitive loss in AD 
as compared to larger fibrillar Aβ aggregates and is consid-
ered the most neurotoxic species (McLean et al., 1999; Dahl-
gren et al., 2002).
In vitro and in vivo studies have shown that Aβ oligomers in-
duce neuronal synaptic loss and degeneration and also reduce 
viability of non-neuronal mammalian cells and non-mamma-
lian cells, including yeast (Bharadwaj et al., 2008; Treusch et 
al., 2011), suggesting a common mechanism for oligomer Aβ42 
induced toxicity shared between different cell types. Yeasts are 
eukaryotic cells and offer greater advantage over other disease 
models mainly due to the ease of manipulation, availability of 
powerful genomic and proteomic tools and high-throughput 
screening techniques. In addition to genetic similarity, yeast 
cells show similarity in numerous metabolic and signaling 
pathways with humans, especially those involved in ageing 
and cellular death. Yeast models have been used extensively to 
study misfolded or aggregated proteins involved in late-onset 
neurodegenerative disorders such as Huntington polygluta-
mine repeats, α-synuclein, superoxide dismutase 1 and Aβ42 
(Bharadwaj et al., 2010). Due to their robust nature and ability 
to effectively coordinate the activities of protective stress re-
sponse pathways to toxic proteins, they are ideally suited for 
investigating disease relevant pathways and for testing of small 
molecules that protect against cell death.
Similar to neuronal cells (Dahlgren et al., 2002), we have 
previously shown that oligomer Aβ42 is significantly more 
toxic than fibrillar Aβ42 and induced dose-dependent cell 
death in yeast (Bharadwaj et al., 2008). This yeast model for 
Aβ42 toxicity have been implemented for investigating the 
neuroprotective effects of whey derived peptides (Bharad-
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waj et al., 2013), functional characterisation of Aβ fusion 
proteins (Caine et al., 2011) and in studying the role of 
autophagy in protection against Aβ42 toxicity (Bharadwaj 
et al., 2012). These assays have been based on colony count-
ing which is time-consuming to set-up and unsuitable for 
screening of gene deletion/overexpression libraries and small 
molecule collections. To increase feasibility for such broad-
based screening methods, here we have developed a growth 
based high-throughput assay based on our established col-
ony-count method to measure oligomer Aβ42 induced cell 
death. This novel assay was further validated by assessing 
known protective agents that promote survival against oligo-
mer Aβ42 mediated cell death.
  
Materials and Methods 
Yeast strain
Wild-type Saccharomyces cerevisiae strain BY4743 [geno-
type: MATa/α his3Δ1/his3Δ1 leu2Δ0/leu2Δ0 LYS2/lys2Δ0 
met15Δ0/MET15 ura3Δ0/ura3Δ0] (Dr. Gabriel Perrone Uni-
versity of New South Wales) was used for this study. Yeast 
cells were grown on YEPD (1% yeast extract; 2% peptone; 
2% dextrose), YNB (yeast nutrient base) synthetic complete 
or nitrogen starvation media, YNB (-N) for toxicity experi-
ments. Yeast cells were stored as glycerol stocks at –80°C and 
in media plates at 4°C.
Reagents
Autophagy modulating compounds including Latrepirdine, 
Rapamycin and SMER28 were used as controls in this study. 
Latrepirdine (Dimebolin dihydrochloride, molecular weight 
(MW): 392.37) was purchased from Biotrend AG, Zurich, 
Switzerland. Latrepirdine was dissolved into sterile double 
distilled water to 30 mM concentration. Rapamycin and 
SMER28 were purchased from Sigma (Missouri, USA) and 
solutions were prepared in DMSO (Dimethyl sulfoxide). 
Freshly prepared working stocks (1 mM) prepared from 
-80ºC frozen stocks were used for all experiments. Synthetic 
human Aβ42 and Aβ16 were purchased from ERI Laboratory 
(Connecticut). Recombinant human insulin (I2643, MW: 
5800 Da) was purchased from Sigma.
Aβ preparation
Aβ peptides were prepared according to Bharadwaj et al. 
(2012). Aβ peptide (0.5 mg) was dissolved in 500 μL hexa-
fluoroisopropanol solution and incubated overnight at room 
temperature. The hexafluoroisopropanol was then evapo-
rated using vacuum and the dried peptide films were stored 
in a –80°C freezer. Aβ peptide films were dissolved in 200 
μL sterile double-distilled water and prepared prior to use. 
The peptide solution was vortexed followed by sonication 
for 5 minutes on ice and then centrifuged for 10 minutes at 
14,000 × g. The resulting supernatant containing soluble Aβ 
oligomers and was used for yeast toxicity assays following 
overnight incubation at room temperature to allow oligom-
erisation. Insulin (MW: 4.8 kDa) was freshly prepared in 1 × 
PBS and truncated Aβ16 (MW: 1.6 kDa) was prepared in a 
similar fashion as Aβ42 for toxicity assays.
Aβ toxicity assay in yeast: colony forming unit assay
Wild-type Saccharomyces cerevisiae (strain, BY4743) was 
used for Aβ toxicity experiments. Yeast cells were stored on 
YEPD agar plates at 4°C. A single colony was inoculated in 
YEPD liquid media and incubated by shaking at 30°C over-
night. The overnight yeast culture was re-inoculated in fresh 
YEPD liquid media and incubated with shaking and grown 
for 3–4 hours at 30°C to reach exponential phase growth. For 
inducing autophagy, cells were washed in sterile water and 
pre-incubated with latrepirdine (5, 10, and 20 µM), rapamy-
cin (50, 100, 150, and 200 nM), SMER28 (small molecule 
enhancer of rapamycin, 10, 20, and 50 µM) or incubated in 
nitrogen starvation media (YNB, -N). These cultures were 
diluted to ~5 × 103 yeast cells/mL in sterile distilled water. 
Cells were then dispensed into 96-well microtitre plates for 
peptide treatments. Vehicle or peptide preparations were 
added to the diluted cell suspension to required concentra-
tions. The final volume in each well was made up to ~100 μL 
and then the microtitre plate was sealed with a gas perme-
able membrane (optional) and incubated at 30°C by shaking 
for time periods as indicated. The cell suspensions were then 
plated on YEPD agar plates and incubated at 30°C for 2 days 
to measure the number of colony-forming units (CFU). Cell 
viability following peptide treatment was calculated from the 
CFU count and represented as percent change compared to 
vehicle treatment.
Absorbance-based growth assay
In this study, we adapted the colony forming unit assay to 
an absorbance-based growth assay using a 96-well plate 
format to increase the feasibility of this yeast model in large 
scale screening techniques. Cells were treated with peptides 
and/or autophagy modulating reagents as described above. 
Exponentially growing yeast cells were treated with increas-
ing doses of oligomeric Aβ42 for 24 hours, and then the cell 
suspensions were supplemented with yeast growth media 
(YEPD, 50 μL) and the growth was measured after 16-hour 
incubation at 30°C by absorbance measurement (optical 
density, OD600 nm) using a spectrophotometer FLUOstar 
Optima plate reader (BMG Labtech, Ortenberg, Germany). 
The cell density measured as absorbance values was rep-
resented as percent cell viability. Cell viability in peptide 
treated samples was evaluated from the absorbance values 
from similar time points as the untreated and represented as 
percent change from vehicle treated.
Statistical analysis
For the colony count assay cell viability was determined by 
counting colonies across the various treatments as described 
previously (Bharadwaj et al., 2008). For the growth assay, the 
mean absorbance values between treatment replicates were 
used to determine cell survival across the various peptide 
treatments used. All comparisons were made using two-
tailed Student’s t-test (equal sample size, unequal variances) 
using GraphPad Prism software version 8 (GraphPad Soft-
ware Inc., La Jolla, CA, USA).
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Results
Oligomer Aβ42 toxicity
Initially, we compared the colony forming unit assay and the 
absorbance-based growth assay to measure oligomer Aβ42 
toxicity (Figure 1). Both assays revealed a dose dependent 
toxicity profile, however colony counting showed greater 
sensitivity at lower Aβ42 concentrations (0.5–2 µM) (Figure 
1B). Both assays were comparable at higher Aβ42 concentra-
tions (4–10 μM) (Figure 1B). We also compared the toxicity 
of oligomer Aβ42 as the positive control and non-aggregating 
C-terminal truncated Aβ16 peptide (MW 1760 Da) and insu-
lin peptide (MW 5800 Da) were used as the negative controls 
(Figure 2). Oligomer Aβ42 showed a dose-dependent loss 
in cell viability, whereas Aβ16 and insulin treatment did not 
alter cell viability at similar concentrations tested (Figure 2). 
It is noted that cell viability analysis using the growth-based 
assay showed 50–80% survival at 2 µM, 40–60% at 4 µM 
and 10% at 10 µM in Figure 1B, whereas Figure 2 showed 
75–85% survival at 2 µM, 50% at 4 µM and 10% at 10 µM. 
Inhibitors of oligomer Aβ42 toxicity
Wild type yeast was incubated in nitrogen depleted media 
(Figure 3A) or treated with latrepirdine (5–20 µM) (Figure 
3B), rapamycin (50–200 nM) (Figure 3C), or SMER28 (10–
50 µM) to induce autophagy followed by oligomer Aβ42 treat-
ment (2–10 µM) (Figure 3D). A dose dependent loss in via-
bility was observed in cells treated with oligomeric Aβ42. Low 
concentrations of Aβ42 (2 µM) showed ~20% cell death and 
higher concentrations ranging 4–10 µM showed 50–80% loss 
in viability. Cell viability following Aβ42 treatment was sig-
nificantly higher in nitrogen starved, latrepirdine, rapamycin 
or SMER28 treated cells compared to vehicle treated (Figure 
3). Notably, only nitrogen starvation showed significant pro-
tection (a 40% increase in viability) against the highest Aβ42 
concentration tested (10 µM). Whereas, latrepirdine, rapa-
mycin and SMER28 increased cell survival (20–60% increase 
in viability) only at lower Aβ42 concentrations (2–5 µM). 
The incubation period with the autophagy enhancers was 
found to be critical for inducing protection against oligomer 
Aβ42 toxicity. Shorter incubation times (6 hours, 30°C) were 
used for latrepirdine, rapamycin and nitrogen starvation. 
However, longer incubations (16 hours, 30°C) were required 
for SMER28 to promote cell viability with Aβ42 treatment 
(Figure 3). The results showed significant differences in the 
levels of protection against oligomer Aβ42 toxicity conferred 
by physiological (nitrogen starvation) and chemical inducers 
(latrepirdine, rapamycin and SMER28) of autophagy.
Discussion
A novel high-throughput assay for measuring oligomer 
Aβ42 toxicity
Cell based high-throughput assays are indispensable for 
analysis of signaling pathways and discovery of small-mol-
ecule modulators of disease processes. The budding yeast, 
Saccharomyces cerevisiae has been broadly employed for 
mechanism-of-action studies and drug target identification. 
Existing high-throughput viability assays such as colony 
count and spotting assay are based on clonogenic analysis 
(Bharadwaj et al., 2010), which measures the effectiveness of 
specific agents on the survival and proliferation of yeast cells 
in agar media. Compared to such clonogenic assays, absor-
bance-based viability assays offer a simple and more sensi-
tive technique for screening gene deletion/overexpression 
libraries and compound repositories. 
In our previous work, we developed a novel assay for 
measuring toxicity of oligomer Aβ42 peptide, a key protein 
associated with pathogenesis and disease development in 
AD (Bharadwaj et al., 2008, 2012). Similar to neuronal cells, 
oligomer Aβ42 was found to be more toxic and induced dose 
dependent cell death in yeast compared to fibrillar Aβ42. The 
original method used a colony count based assay to mea-
sure oligomer Aβ42 toxicity (Bharadwaj et al., 2008). In this 
study, we have developed and validated an absorbance based 
high-throughput assay to measure toxicity of oligomer Aβ42. 
It is noted that cell viability analysis using the growth-based 
assay showed slight variability in Figures 1B and 2. It is likely 
that the differences in the standard deviation is due to the 
number of replicates conducted for experiments in Figures 
1B (n = 8) and 2 (n = 12). However, the overall level of toxici-
ty observed in Figures 1B and 2 are consistent. Notably, both 
the colony count and the absorbance-based growth assay 
in yeast showed significant loss in cell viability at oligomer 
Aβ42 concentrations (≥ 1 μM) required to induce toxicity in 
neuronal cells (Dahlgren et al., 2002). This yeast assay offers a 
robust and high-throughput cell-based platform for analysis 
of disease relevant pathways and screening compounds that 
can alleviate oligomer Aβ42 induced cell death. 
Previous studies have developed high-throughput yeast 
assays to measure Aβ42 induced toxicity by targeting it to 
the secretory pathway (Treusch et al., 2011) or used strains 
expressing Aβ42 fused to the essential functional domain of 
Sup35, a prion protein, to measure Aβ42 oligomerization (Park 
et al., 2011). Some of the advantages of our yeast model com-
pared to the studies of Park et al. and Treusch et al. include 1) 
ability to test toxicity of different Aβ peptides and its various 
isoforms and 2) suitability for genetic screening as the assay 
uses structurally characterized synthetic Aβ42 preparations 
and eliminate the effects of gene deletion/overexpression 
on Aβ42 production. Also, the use of an absorbance-based 
growth assay increases its suitability for screening gene de-
letion/overexpression and drug libraries as compared to the 
use of fluorescent/colorimetric dyes which has limitations 
due to likelihood of toxicity in certain mutants, interference 
with cell metabolism and fluorescent/colorimetric assay read 
out. Overall, data from the absorbance-based assay indicat-
ed its suitability for large scale, high-throughput screening 
methods and offers a robust cell-based platform for analysis 
of disease relevant pathways and screening compounds that 
can alleviate oligomer Aβ42 induced cell death.
Induction of autophagy protects against oligomer Aβ42 
toxicity
A wide range of inhibitors of Aβ42 aggregation, including 
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Figure 1 Comparative analysis of oligomer Aβ42 toxicity in yeast by colony count and the absorbance-based high-throughput assay. 
(A) Exponentially growing yeast cells in YEPD (1% yeast extract; 2% peptone; 2% dextrose) media were serially diluted in sterile double distilled 
water and treated with oligomer Aβ42 peptide for 24 hours. Following treatment, the cell suspensions were supplemented with fresh YEPD media 
and the growth/cell density was monitored for 16 hours at 30°C by absorbance measurement (optical density, OD600). (B) The absorbance values 
measured at 16 hours are represented as percent cell viability for each treatment and directly compared to those values obtained with the estab-
lished colony count assay (Bharadwaj et al., 2008). Although less sensitive at low concentrations (1–2 μM) of oligomer Aβ treatment compared to 
the colony count assay, the high-throughput assay shows dose-dependent loss of viability with oligomer Aβ42 treatment, compared to vehicle treat-
ment. Statistical significance between treatments was assessed using two-tailed Student’s t-test (n = 8, Aβ42 treated vs. untreated, *P < 0.05, **P < 
0.01). (C) Images showing the colony count and the high-throughput assay. Aβ: Amyloid β protein.
Figure 2 Toxicity of oligomer Aβ42, Aβ16 and insulin peptides. 
Exponentially growing yeast cells in YEPD (1% yeast extract; 2% pep-
tone; 2% dextrose) media were serially diluted in sterile double distilled 
water and treated with oligomer Aβ42, Aβ16 and insulin peptide prepa-
rations for 24 hours. Oligomer Aβ42 treatment showed dose dependent 
loss of viability, whereas Aβ16 and insulin treatment were significantly 
less toxic as compared to vehicle treated. Statistical significance between 
treatments was assessed using two-tailed Student’s t-test (n = 12, Aβ42 
treated vs. untreated, *P < 0.05, **P < 0.01). Aβ: Amyloid β protein.
peptide and small molecules of natural and synthetic origin 
have been shown to regulate toxicity of Aβ42 (Mangialasche 
et al., 2010). An important caveat in designing such inhib-
itors is to target the toxic form of Aβ42 and identify com-
pounds with low cytotoxicity. In addition to inhibiting the 
formation or disaggregating the Aβ42 toxic oligomer struc-
tures, there is growing interest towards inducing effective 
cellular responses to Aβ42 induced toxicity and cell death, and 
thereby suppress the downstream apoptotic cascades and 
necrosis in the AD brain. A cellular pathway that can confer 
such protection is autophagy (Nixon, 2013). Autophagy is a 
vital intracellular catabolic pathway that plays an important 
role in the removal of aggregated or misfolded proteins in 
neurodegenerative diseases. Modulation of autophagy can 
enhance protective responses to toxicity, and suppress apop-
totic cascades or necrosis leading to neurodegeneration in 
the brain (Mputhia et al., 2019). 
Substantial benefits have been observed with autopha-
gy-inducing agents in various neurodegenerative disease 
models (Nixon, 2013). A widely used inducer of autophagy, 
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Figure 3 Induction of autophagy protects against oligomer Aβ42 toxicity in yeast. 
Exponentially growing yeast cells were incubated in (A) nitrogen depleted media or (B) YNB (yeast nutrient base)-synthetic complete media 
containing autophagy modulating compounds, i.e., latrepirdine (5, 10 and 20 μM) or (C) rapamycin (50, 100, 150 and 200 nM) and (D) SMER28 
(10, 20 and 50 µM)) at 30°C to induce autophagy followed by oligomer Aβ treatment. Loss of cell viability from the different treatments was then 
measured using the absorbance-based Aβ42 toxicity assay. Cell viability following oligomer Aβ42 treatment was significantly higher in nitrogen 
starved or latrepirdine treated wild type cells compared to vehicle treated. Statistical significance between treatments was assessed using two-tailed 
Student’s t-test (Different Aβ42 treated groups were compared. In the Aβ42 treated groups, control cells and cells treated with autophagy modulators 
were compared. *P < 0.05, **P < 0.01). Only nitrogen starvation showed significant protection (40% increase in viability) against 10 μM Aβ42. La-
trepirdine, rapamycin and SMER28 increased cell survival (20–40% increase in viability) only at 2–5 μM Aβ42. Aβ: Amyloid  β protein.
get of rapamycin) (Huang et al., 2004). Rapamycin has been 
shown to reduce Aβ induced neurodegeneration and im-
prove cognition in transgenic mouse models (Spilman et al., 
2010). An mTOR-independent autophagy inducer, SMER28 
(small-molecule enhancer of rapamycin) (Huang et al., 2004) 
has shown to reduce the levels of Aβ and alleviate toxicity 
in Huntington disease model (Tian et al., 2011). Recently, 
we showed that enhanced autophagic activity mediated by 
rapamycin and a pro-neurogenic compound, latrepirdine 
protected yeast cells against oligomer Aβ42 toxicity (Bharad-
waj et al., 2012). We also showed that latrepirdine enhanced 
mTOR- and Atg5-dependent autophagy and improved 
cognition in AD mouse model (Steele et al., 2012). Here, 
we validated the use of the absorbance-based Aβ42 toxicity 
assay by determining the protective ability of different class-
es of autophagy enhancers. The results showed significant 
differences in the levels of protection against oligomer Aβ42 
toxicity conferred by physiological (nitrogen starvation) and 
chemical inducers (latrepirdine, rapamycin and SMER28) 
of autophagy. These findings indicate how autophagy can be 
modulated distinctly by different cellular pathways of induc-
tion and how they respond to increasing levels of toxicity 
and cellular damage caused by oligomeric Aβ42.
Previous studies favour a strategy of enhancing the efficacy 
of autophagy by preventing or reversing the impairments of 
the specific processes that are disrupted. Several compounds 
with autophagy-related functions as the primary or second-
ary drug target have been trialled for several neurodegener-
ative diseases including AD (Nixon, 2013). Although auto-
phagy activation is a promising intervention, there are some 
caveats to consider (Sarkar, 2013; Mputhia et al., 2019). In 
diseases like AD, where there is a pre-existing impairment in 
autophagy, the success of any autophagy-based intervention 
may depend on whether lysosomal clearance is functional 
(Nixon, 2013; Mputhia et al., 2019; Tripathi et al., 2019). In 
addition, effects of autophagy activation may also vary sig-
nificantly depending on the physiological state of the cell, 
especially during proteotoxic stress. In fact, some studies 
suggest that autophagy activation may be harmful in ageing 
conditions with pre-existing pathology (Carosi and Sargeant, 
2019; Tripathi et al., 2019).
In summary, our previous work (Bharadwaj et al., 2012) 
together with the current findings provides evidence for 
autophagy as a preventative treatment against oligomer Aβ42 
mediated cell death. In addition, here we have established 
the potential use of the high-throughput yeast assay as a bi-
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ological screen to dissect disease-relevant pathways and net-
work of genes that mediate protection against Aβ42-induced 
cell death. Although yeast is an excellent screening model 
for inhibitors of Aβ42 toxicity, it has limitations due to lack 
of specialized neuronal structures and functions. However, 
such cell-based systems are necessary for drug discovery 
and genetic screening, where large, diverse small molecule 
collections can be tested for their therapeutic efficacy in 
AD. Such biological assays can cast a much wider net in the 
discovery of potential leads and even identify undesirable 
targets of drugs as compared to target-by-target approaches.
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